Evolus Inc (NASDAQ:EOLS)’s share price traded up 5.9% during mid-day trading on Friday . The stock traded as high as $16.50 and last traded at $16.33. 688,100 shares were traded during mid-day trading, an increase of 87% from the average session volume of 368,810 shares. The stock had previously closed at $15.42.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Evolus from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a report on Thursday, July 26th. Cantor Fitzgerald reissued a “buy” rating and issued a $35.00 price objective on shares of Evolus in a report on Monday, September 17th. SunTrust Banks reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Monday, August 6th. Finally, JMP Securities reissued an “outperform” rating and issued a $35.00 price objective on shares of Evolus in a report on Thursday, August 2nd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $30.40.
The firm has a market cap of $376.12 million and a PE ratio of -60.57.
Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Thursday, August 2nd. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.05). On average, equities research analysts predict that Evolus Inc will post -1.76 EPS for the current year.
In other Evolus news, Director Kristine Romine purchased 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 22nd. The stock was purchased at an average price of $19.83 per share, for a total transaction of $198,300.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael M. Jafar purchased 12,800 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The stock was acquired at an average price of $20.83 per share, with a total value of $266,624.00. The disclosure for this purchase can be found here.
Several institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in shares of Evolus in the 2nd quarter valued at about $108,000. Wells Fargo & Company MN increased its stake in shares of Evolus by 860.3% in the 3rd quarter. Wells Fargo & Company MN now owns 5,944 shares of the company’s stock valued at $110,000 after purchasing an additional 5,325 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Evolus by 761.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,555 shares of the company’s stock valued at $183,000 after purchasing an additional 5,794 shares in the last quarter. Schwab Charles Investment Management Inc. purchased a new position in shares of Evolus in the 2nd quarter valued at about $258,000. Finally, Alpine Woods Capital Investors LLC purchased a new position in shares of Evolus in the 2nd quarter valued at about $280,000. Hedge funds and other institutional investors own 13.13% of the company’s stock.
About Evolus (NASDAQ:EOLS)
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Featured Story: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.